Abstract
Background Male hypogonadism arises from a deficiency in testosterone secretion that may occur naturally with increasing age, or as a result of malfunction of the hypothalamus, pituitary gland or testes. Tostran ® (also known as Fortigel ®, Itnogen ® and Tostrex ®) is a metered-dose gel formulation of 2% testosterone that was recently developed to treat male hypogonadism and to overcome the disadvantages exhibited by some testosterone formulations. Methods A prospective Phase II trial of Tostran in men with primary or secondary hypogonadism evaluating the effect of showering was conducted. Results This trial demonstrated that showering 2 h after application of Tostran has no significant effect on serum testosterone levels. Conclusion Market research in the UK and Germany has indicated that endocrinologists would consider switching patients to Tostran from other formulations, especially other gels. Their preference is due to the dosage and administration advantages of Tostran, the flexibility of the metered-dose formulation, and the ability to shower 2 h after application.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
